Compare Davita Inc (DVA) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Veritone Inc — how do they compare? Davita Inc trades at $229.45 (market cap $14.92B), while Veritone Inc trades at $1.07 (market cap $98.53M). The key difference: Davita Inc is far larger — about 151.4× Veritone Inc's market cap, and Davita Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VERI | |
|---|---|---|
Market Cap | $14.92B | $98.53M |
Sector | Health | Technology |
52-Week High | $235.71 | $8.39 |
52-Week Low | $103.87 | $1.07 |
Enterprise Value | $27.47B | $130.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Veritone (VERI) trades at $1.10, down 6.78% in the last 24 hours, with a bearish technical signal despite oversold RSI readings. The company reported revenue of $92.19 million in 2025 but posted a net loss of $111.73 million, with negative profit margins and cash flow challenges. Recent news highlights multiple class action lawsuits alleging securities fraud, creating significant legal overhangs.
Investment outlook remains highly speculative given persistent losses and legal uncertainties. While analyst consensus shows mixed sentiment with 46% buy ratings, fundamental weaknesses and ongoing litigation pose substantial risks. The stock's current valuation at 0.88x sales offers limited protection against operational challenges and potential legal liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
